Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Jump-Start Your Search For Promising Trade Ideas With Barchart Premier’s "Top Stock Pick". FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Ocugen Inc (OCGN)

Ocugen Inc (OCGN)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 573,820
  • Shares Outstanding, K 327,897
  • Annual Sales, $ 4,410 K
  • Annual Income, $ -67,850 K
  • EBIT $ -60 M
  • EBITDA $ -56 M
  • 60-Month Beta 2.75
  • Price/Sales 138.95
  • Price/Cash Flow N/A
  • Price/Book N/A

Options Overview Details

View History
  • Implied Volatility 131.20% (-5.88%)
  • Historical Volatility 115.00%
  • IV Percentile 48%
  • IV Rank 9.87%
  • IV High 544.02% on 11/14/25
  • IV Low 86.00% on 01/08/26
  • Expected Move (DTE 17) 0.3400 (19.10%)
  • Put/Call Vol Ratio 0.22
  • Today's Volume 1,589
  • Volume Avg (30-Day) 4,473
  • Put/Call OI Ratio 0.17
  • Today's Open Interest 82,930
  • Open Int (30-Day) 74,814
  • Expected Range 1.4400 to 2.1200

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 8 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/26
See More
  • Average Estimate $-0.05
  • Number of Estimates 3
  • High Estimate $-0.05
  • Low Estimate $-0.06
  • Prior Year $-0.05
  • Growth Rate Est. (year over year) unch

Price Performance

See More
Period Period Low Period High Performance
1-Month
1.5400 +17.86%
on 03/09/26
2.7250 -33.39%
on 03/17/26
-0.0050 (-0.27%)
since 02/27/26
3-Month
1.3100 +38.55%
on 02/09/26
2.7250 -33.39%
on 03/17/26
+0.4050 (+28.72%)
since 12/26/25
52-Week
0.5700 +218.42%
on 04/09/25
2.7250 -33.39%
on 03/17/26
+1.0155 (+127.02%)
since 03/28/25

Most Recent Stories

More News
Ocugen Announces Topline 12-month Data from Phase 2 ArMaDa Clinical Trial Evaluating OCU410 Modifier Gene Therapy for Geographic Atrophy Secondary to Dry Age-Related Macular Degeneration

Optimal dose intended for Phase 3 demonstrates statistically significant reduction in lesion growth (31%) versus control at 12 months (p< 0.05) Potential 2X treatment benefit compared to 15% and 22%...

OCGN : 1.8150 (+3.71%)
Ocugen to Host Webcast on Tuesday, March 24 at 8 a.m. EDT to Discuss Phase 2 Clinical Trial Data for OCU410—Modifier Gene Therapy for Geographic Atrophy

MALVERN, Pa., March 23, 2026 (GLOBE NEWSWIRE) -- Ocugen, Inc. (“Ocugen” or the “Company”) (NASDAQ: OCGN), a pioneering biotechnology leader in gene therapies for blindness diseases, today announced...

OCGN : 1.8150 (+3.71%)
Ocugen: Q4 Earnings Snapshot

Ocugen: Q4 Earnings Snapshot

OCGN : 1.8150 (+3.71%)
Ocugen Provides Business Update with Fourth Quarter and Full Year 2025 Financial Results

Enrollment for the OCU400 Phase 3 liMeliGhT clinical trial—the first and largest gene therapy registrational trial for broad retinitis pigmentosa patients—was completed. Topline Phase 3 data expected...

OCGN : 1.8150 (+3.71%)
Investors Eye Explosive Growth in Anti-Aging Therapies as Market Targets $420B Milestone

EQNX::TICKER_START (OTCQB:AVAI),(NASDAQ:GERN),(NASDAQ:NTLA),(NASDAQ:NAGE),(NASDAQ:OCGN) EQNX::TICKER_END

AVAI : 0.3200 (+10.34%)
NAGE : 4.41 (+3.04%)
GERN : 1.4900 (+5.67%)
NTLA : 12.81 (+9.96%)
OCGN : 1.8150 (+3.71%)
Ocugen Announces Phase 3 liMeliGhT Enrollment Completion for OCU400, a Novel Modifier Gene Therapy for Broad Retinitis Pigmentosa

Enrollment for liMeliGhT, the first and largest gene therapy registrational trial for broad retinitis pigmentosa (RP) patients, was completed, reflecting strong interest from investigators and patients...

OCGN : 1.8150 (+3.71%)
Ocugen to Host Conference Call on Wednesday, March 4, 2026 at 8:30 A.M. ET to Discuss Business Updates and Fourth Quarter and Full Year 2025 Financial Results

MALVERN, Pa., Feb. 18, 2026 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a pioneering biotechnology leader in gene therapies for blindness diseases, today announced that it...

OCGN : 1.8150 (+3.71%)
Ocugen Appoints Rita Johnson-Greene to Chief Financial Officer

MALVERN, Pa., Feb. 09, 2026 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a pioneering biotechnology leader in gene therapies for blindness diseases, today announced the appointment...

OCGN : 1.8150 (+3.71%)
Ocugen, Inc. Announces Closing of $22.5 Million Underwritten Registered Direct Offering of Common Stock

MALVERN, Pa., Jan. 23, 2026 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Nasdaq: OCGN), a pioneering biotechnology leader in gene therapies for blindness diseases, today announced the closing of its previously...

OCGN : 1.8150 (+3.71%)
Ocugen, Inc. Announces Pricing of $22.5 Million Offering of Common Stock

MALVERN, Pa., Jan. 21, 2026 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Nasdaq: OCGN), a pioneering biotechnology leader in gene therapies for blindness diseases, today announced the pricing of its underwritten...

OCGN : 1.8150 (+3.71%)

Business Summary

Ocugen Inc. is a clinical stage biopharmaceutical company. It is focused on discovering, developing and commercializing therapies which address rare and underserved eye diseases. The company's product pipeline consists of OCU400, OCU300, OCU100 and OCU200 which are in clinical stage. Ocugen Inc., formerly...

See More

Key Turning Points

3rd Resistance Point 1.9767
2nd Resistance Point 1.9233
1st Resistance Point 1.8367
Last Price 1.8150
1st Support Level 1.6967
2nd Support Level 1.6433
3rd Support Level 1.5567

See More

52-Week High 2.7250
Fibonacci 61.8% 1.9018
Last Price 1.8150
Fibonacci 50% 1.6475
Fibonacci 38.2% 1.3932
52-Week Low 0.5700

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.